Article
Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
24 Nov 2011
Abstract excerpt
BACKGROUND: Hemophilia A is a bleeding disorder caused by deficiency in coagulation factor VIII. Recombinant factor VIII (rFVIII) is an alternative to plasma-derived FVIII for the treatment of hemophilia A. However, commercial manufacturing of rFVIII products is inefficient and costly and is associated to high prices and product shortage, even in economically privileged countries. This situation may be solved by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
